CGON
CG Oncology, Inc. Common stockKey Statistics
About CG Oncology, Inc. Common stock
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing pioneering cancer therapies, particularly through its lead product, CG0070, an oncolytic virus therapy designed for non-muscle invasive bladder cancer. Committed to addressing significant unmet medical needs in the oncology space, the company is well-positioned to enhance patient outcomes and transform existing treatment paradigms. As CG Oncology progresses through clinical trials and regulatory processes, its proprietary technology platform sets it apart in the competitive oncology landscape, presenting compelling investment opportunities for institutional investors keen on advancing innovations that may substantially influence cancer care.
Fundamentals
| Revenue (TTM) | $5.07M |
| Gross Profit (TTM) | $-135.44M |
| EBITDA | $-212.70M |
| Operating Margin | -6130.00% |
| Return on Equity | -20.80% |
| Return on Assets | -14.40% |
| Revenue/Share (TTM) | $0.06 |
| Book Value | $12.40 |
| Price-to-Book | 5.19 |
| Price-to-Sales (TTM) | 1117.53 |
| EV/Revenue | 906.79 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1983.00% |
| Shares Outstanding | $88.20M |
| Float | $65.82M |
| % Insiders | 0.23% |
| % Institutions | 108.75% |
Historical Volatility
Volatility is currently expanding